{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:35:46Z","timestamp":1787070946149,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>There are emerging but inconsistent evidences about anti-epileptic drugs (AEDs) as radio- or chemo-sensitizers to improve survival in glioblastoma patients. We conducted a nationwide population-based study to evaluate the impact of concurrent AED during post-operative chemo-radiotherapy on outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods:<\/jats:title>\n                    <jats:p>A total of 1057 glioblastoma patients were identified by National Health Insurance Research Database and Cancer Registry in 2008\u20132015. Eligible criteria included those receiving surgery, adjuvant radiotherapy and temozolomide, and without other cancer diagnoses. Survival between patients taking concurrent AED for 14 days or more during chemo-radiotherapy (AED group) and those who did not (non-AED group) were compared, and subgroup analyses for those with valproic acid (VPA), levetiracetam (LEV), or phenytoin were performed. Multivariate analyses were used to adjust for confounding factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      There were 642 patients in the AED group, whereas 415 in the non-AED group. The demographic data was balanced except trend of more patients in the AED group had previous drug history of AEDs (22.6% vs. 18%, P 0.078). Overall, the AED group had significantly increased risk of mortality (HR = 1.18,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      0.016) compared to the non-AED group. Besides, an adverse dose\u2013dependent relationship on survival was also demonstrated in the AED group (HR = 1.118,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      0.0003). In subgroup analyses, the significant detrimental effect was demonstrated in VPA group (HR = 1.29,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      0.0002), but not in LEV (HR = 1.18,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      0.079) and phenytoin (HR = 0.98,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      0.862).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Improved survival was not observed in patients with concurrent AEDs during chemo-radiotherapy. Our real-world data did not support prophylactic use of AEDs for glioblastoma patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_750_22","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T17:01:57Z","timestamp":1714496517000},"page":"555-562","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Anti-epileptic drug use during adjuvant chemo-radiotherapy is associated with poorer survival in patients with glioblastoma: A nationwide population-based cohort study"],"prefix":"10.4103","volume":"20","author":[{"given":"Peng-Yi","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Show-Chwan Memorial Hospital, No. 542, Section 1 CHUNG-SHAN Road, Changhua, Taiwan"},{"name":"Department of Radiation Oncology, Lin Shin Hospital, No. 36, Section 3 Huizhong Road, Taichung, Taiwan"},{"name":"Department of Radiation Oncology, China Medical University Beigang Hospital, Yunlin, Taiwan"},{"name":"Department of Radiation Oncology, China Medical University Hospital, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Wei","sequence":"additional","affiliation":[{"name":"Division of Family Medicine, Department of Community Medicine, China Medical University Hospital, Taichung, Taiwan"},{"name":"Division of Occupational Medicine, Department of Community Medicine, China Medical University Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-San Clifford","family":"Chao","sequence":"additional","affiliation":[{"name":"China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Nan","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, China Medical University Hospital, China Medical University, Taichung, Taiwan"},{"name":"Graduate Institute of Medical Science, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hui","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, China Medical University Hospital, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ti-Hao","family":"Wang*","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, China Medical University Hospital, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3171\/jns.1978.49.3.0333","article-title":"Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial","volume":"49","author":"Walker","year":"1978","journal-title":"J Neurosurg"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM198012043032303","article-title":"Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery","volume":"303","author":"Walker","year":"1980","journal-title":"N Engl J Med"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/1097-0142(19810215)47:4<649::AID-CNCR2820470405>3.0.CO;2-W","article-title":"Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time:A prospective multicenter trial of the Scandinavian Glioblastoma Study Group","volume":"47","author":"Kristiansen","year":"1981","journal-title":"Cancer"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/jns.1989.71.1.0001","article-title":"Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001","volume":"71","author":"Shapiro","year":"1989","journal-title":"J Neurosurg"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.30.9.907","article-title":"Assumptions in the radiotherapy of glioblastoma","volume":"30","author":"Hochberg","year":"1980","journal-title":"Neurology"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3171\/jns.1987.66.6.0865","article-title":"Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms","volume":"66","author":"Kelly","year":"1987","journal-title":"J Neurosurg"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study:5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4143\/crt.2014.026","article-title":"In Vitro and in vivo radiosensitizing effect of valproic acid on fractionated irradiation","volume":"47","author":"Chie","year":"2015","journal-title":"Cancer Res Treat"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"35004","DOI":"10.18632\/oncotarget.5253","article-title":"Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells","volume":"6","author":"Thotala","year":"2015","journal-title":"Oncotarget"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/neuonc\/noq044","article-title":"Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide","volume":"12","author":"Bobustuc","year":"2010","journal-title":"Neuro Oncol"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12935-018-0626-8","article-title":"Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis","volume":"18","author":"Scicchitano","year":"2018","journal-title":"Cancer Cell Int"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1159\/000485753","article-title":"cellular effects of the antiepileptic drug valproic acid in glioblastoma","volume":"44","author":"Eckert","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"R14-20241021","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","article-title":"A Phase 2 Study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma","volume":"92","author":"Krauze","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1200\/JCO.2015.63.6563","article-title":"Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma","volume":"34","author":"Happold","year":"2016","journal-title":"J Clin Oncol"},{"key":"R16-20241021","doi-asserted-by":"crossref","first-page":"e0225599","DOI":"10.1371\/journal.pone.0225599","article-title":"Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme:A retrospective, single-center study","volume":"14","author":"Ryu","year":"2019","journal-title":"PLoS One"},{"key":"R17-20241021","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijrobp.2013.02.012","article-title":"Valproic acid use during radiation therapy for glioblastoma associated with improved survival","volume":"86","author":"Barker","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R18-20241021","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","article-title":"Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma","volume":"77","author":"Weller","year":"2011","journal-title":"Neurology"},{"key":"R19-20241021","first-page":"9877","article-title":"Effects of valproic acid on the susceptibility of human glioma stem cells for TMZ and ACNU","volume":"15","author":"Li","year":"2018","journal-title":"Oncol Lett"},{"key":"R20-20241021","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/neuonc\/nov238","article-title":"Prognostic relevance of epilepsy at presentation in glioblastoma patients","volume":"18","author":"Berendsen","year":"2016","journal-title":"Neuro Oncol"},{"key":"R21-20241021","first-page":"76","article-title":"Prognostic significance of seizure in patients with glioblastoma multiforme","volume":"52","author":"Ozbek","year":"2004","journal-title":"Neurol India"},{"key":"R22-20241021","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12885-019-6511-6","article-title":"Prognostic factors of patients with Gliomas-An analysis on 335 patients with Glioblastoma and other forms of Gliomas","volume":"20","author":"Liang","year":"2020","journal-title":"BMC Cancer"},{"key":"R23-20241021","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2176\/nmc.oa.2017-0167","article-title":"Prognostic factors in glioblastoma:Is there a role for epilepsy?","volume":"58","author":"Dobran","year":"2018","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"R24-20241021","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1212\/WNL.54.10.1886","article-title":"Practice parameter:Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"54","author":"Glantz","year":"2000","journal-title":"Neurology"},{"key":"R25-20241021","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3747\/co.v13i6.107","article-title":"The use of prophylactic anticonvulsants in patients with brain tumours-A systematic review","volume":"13","author":"Perry","year":"2006","journal-title":"Curr Oncol"},{"key":"R26-20241021","doi-asserted-by":"crossref","first-page":"40896","DOI":"10.18632\/oncotarget.5683","article-title":"IDH mutation and MGMT promoter methylation in glioblastoma:Results of a prospective registry","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"key":"R27-20241021","doi-asserted-by":"crossref","first-page":"e30339","DOI":"10.1371\/journal.pone.0030339","article-title":"Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma:A report of 118 patients from China","volume":"7","author":"Yan","year":"2012","journal-title":"PLoS One"},{"key":"R28-20241021","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.7150\/jca.38603","article-title":"Practice of the new integrated molecular diagnostics in gliomas:Experiences and new findings in a single Chinese center","volume":"11","author":"Hu","year":"2020","journal-title":"J Cancer"},{"key":"R29-20241021","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ijrobp.2011.12.086","article-title":"MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy:A single-institution study","volume":"84","author":"Kim","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R30-20241021","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1007\/s11064-014-1435-7","article-title":"The prognosis of MGMT promoter methylation in glioblastoma patients of different race:A meta-analysis","volume":"39","author":"Yang","year":"2014","journal-title":"Neurochem Res"},{"key":"R31-20241021","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.arcmed.2013.04.004","article-title":"MGMT promoter methylation and glioblastoma prognosis:A systematic review and meta-analysis","volume":"44","author":"Chen","year":"2013","journal-title":"Arch Med Res"},{"key":"R32-20241021","doi-asserted-by":"crossref","first-page":"17354","DOI":"10.18632\/oncotarget.4008","article-title":"Prognostic role of IDH mutations in gliomas:A meta-analysis of 55 observational studies","volume":"6","author":"Xia","year":"2015","journal-title":"Oncotarget"},{"key":"R33-20241021","first-page":"noac197","article-title":"IDH1\/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1\/2 wildtype glioblastomas","author":"van Opijnen","year":"2022","journal-title":"Neuro Oncol"},{"key":"R34-20241021","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2022.2844","article-title":"World Health Organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas:A review","author":"Berger","year":"2022","journal-title":"JAMA Oncol"},{"key":"R35-20241021","first-page":"803","article-title":"The 2021 WHO Classification of Tumors, 5th edition, Central nervous system tumors:A short review","volume":"74","author":"Komori","year":"2022","journal-title":"Brain Nerve"},{"key":"R36-20241021","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1471-2288-13-92","article-title":"A tutorial on sensitivity analyses in clinical trials:The what, why, when and how","volume":"13","author":"Thabane","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"R37-20241021","doi-asserted-by":"crossref","first-page":"e77301","DOI":"10.1371\/journal.pone.0077301","article-title":"Statistical trends in the Journal of the American Medical Association and implications for training across the continuum of medical education","volume":"8","author":"Arnold","year":"2013","journal-title":"PLoS One"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_750_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:39:22Z","timestamp":1787067562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_750_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_750_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"2022-04-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}